Autolus Therapeutics plc — FY 2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022. Although the request metadata says “2022 Q4,” this filing is an annual report and does not provide standalone fourth-quarter results. Financial statements are prepared under U.S. GAAP and presented in U.S. dollars.
Business context
Autolus is a clinical-stage biopharmaceutical company developing programmed T-cell therapies for cancer. It had no approved products and generated no commercial product sales. Its lead candidate, obe-cel, was being studied for relapsed or refractory adult B-cell acute lymphoblastic leukemia (ALL); other programs included AUTO1/22, AUTO4, AUTO6NG and AUTO8.
Key financial metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Grant income | $0.2 million | $0.8 million |
| License revenue | $6.2 million | $1.5 million |
| Research and development expense | $142.0 million | $134.8 million |
| General and administrative expense | $31.9 million | $31.9 million |
| Net loss | $148.8 million | $142.1 million |
| Net loss per ordinary share | $1.57 | $1.97 |
| Net cash used in operating activities | $112.3 million | $117.9 million |
| Cash and cash equivalents at year-end | $382.4 million | $310.3 million |
| Total assets | $490.3 million | $405.6 million |
| Total liabilities | $191.6 million | $92.2 million |
| Liability for future royalties and sales milestones | $125.9 million | $47.0 million |
License revenue was principally from Moderna option exercise and license fees and an upfront payment from Bristol Myers Squibb. There was no product revenue. Gross margin is not meaningful for this pre-commercial business. Year-end net current assets were $379.4 million. Lease liabilities totaled $24.3 million; the filing reports no conventional borrowings in the figures provided.
Investing activities used $10.8 million, primarily for property and equipment. Financing activities provided $223.6 million, including $153.5 million net proceeds from the December 2022 public offering and $70.0 million in Blackstone development payments. Cash and restricted cash increased by $72.1 million; foreign-exchange movements reduced cash by $28.4 million.
Material changes versus prior year
- License revenue increased by $4.7 million to $6.2 million, but remained small relative to operating expenses.
- R&D expense rose $7.2 million, mainly due to higher obe-cel clinical and manufacturing costs; G&A expense was essentially unchanged.
- Net loss widened by $6.7 million. Higher interest expense, largely non-cash and associated with the Blackstone arrangement, contributed to the increase.
- Operating cash use improved by $5.6 million, while year-end cash rose $72.1 million, supported by equity issuance and Blackstone payments.
- The December offering issued 81.9 million ADSs at $2.00 each and raised $152.4 million net. Ordinary shares outstanding increased to 173.1 million from 90.9 million at year-end 2021.
- Accumulated deficit increased to $670.2 million from $521.3 million. Foreign-currency translation loss was $30.3 million in 2022.
Outlook, management commentary, risks and unusual items
- Management stated that year-end cash of $382.4 million was expected to fund current planned operations and capital requirements for at least 12 months from the report date. The going-concern assessment considered forecasts through 2024, including downside scenarios; additional funding will be needed before expected cash breakeven.
- The company expected to submit an obe-cel BLA to the FDA at the end of 2023, subject to clinical, regulatory and manufacturing progress. In the FELIX study, an interim analysis of 50 patients showed a 70% overall remission rate and met the primary endpoint. Across 92 treated patients, Grade 3 or higher CRS was reported in 3% and Grade 3 or higher ICANS in 8%.
- Management expected further clinical updates in 2023, including obe-cel, AUTO1/22, AUTO4 and AUTO8 data, and planned to initiate an AUTO6NG clinical trial. These are forward-looking plans, not assured outcomes.
- The 70,000-square-foot Nucleus manufacturing facility in Stevenage was being fitted out; the first clean room was made available in November 2022. The facility requires completion, qualification and regulatory approval before commercial use. The company disclosed limited manufacturing redundancy and dependence on third-party suppliers and facilities.
- Blackstone had paid $120 million of a potential $150 million development financing commitment by year-end, with $30 million remaining subject to regulatory milestones. In return, Autolus agreed to mid-single-digit royalties and sales milestone payments, secured by a lien over specified assets and subject to restrictive covenants. The related liability was $125.9 million at year-end; its measurement depends on significant estimates.
- Key risks include continued losses and need for financing; clinical, regulatory and safety uncertainty; manufacturing scale-up and supply-chain execution; competition; reimbursement and pricing; and intellectual-property challenges. The filing notes third-party U.S. patents potentially covering obe-cel were expected to expire between 2023 and 2025 and that U.S. launch timing could be affected if rights are not resolved.
- Other notable exposures include potential dilution from future capital raises, foreign-exchange risk without current hedging, and a possible PFIC classification for U.S. tax purposes. The company also reported that it was assessing potential U.K. VAT treatment that could affect past VAT recoveries.
- The company reported no material legal proceedings. The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Whether the complete FELIX results support an FDA submission on the stated timetable, and how response durability and safety compare with competing therapies.
- Whether the Nucleus facility is completed, qualified and licensed on schedule, with adequate capacity, product quality and vein-to-vein delivery performance.
- Remaining cash runway under updated operating plans, the expected burn rate, and the timing and terms of any additional financing.
- The final economics and restrictions of the Blackstone agreement, including the remaining milestone payment, royalty cap, security interest and liability estimates.
- The status of potential U.S. obe-cel patent issues and their implications for launch timing and commercial rights.
- Whether U.K. R&D tax-credit changes and the VAT review affect future cash receipts or could require repayment of previously recovered VAT.